Weekly shot could slow kidney damage in CKD patients
NCT ID NCT07206290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a weekly injection called survodutide in 120 people with chronic kidney disease and high protein in their urine. The goal is to see if the drug can lower protein levels and protect kidney function over 36 weeks. Participants must be on stable standard treatments like ACE inhibitors or ARBs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk